Advertisement

Journal of Neural Transmission

, Volume 114, Issue 5, pp 629–634 | Cite as

Meta-analysis: the efficacy of nootropic agent Cerebrolysin in the treatment of Alzheimer’s disease

  • Z.-H. Wei
  • Q.-B. He
  • H. Wang
  • B.-H. Su
  • H.-Z. Chen
Article

Summary.

To determine the therapeutic effect of nootropic agent Cerebrolysin on patients with mild to moderate Alzheimer’s disease (AD), we searched the Cochrane Library, Medline, PubMed, and Chinese Biomedical Literature Analysis and Retrieval System for Compact Disc (CBMDISC), and communicated with EBEWE Pharmaceutical Ltd, for randomized trials comparing Cerebrolysin with placebo in AD. Available data on clinical global impression, cognitive performance and activities of daily living were extracted from 6 randomized double-blind placebo-controlled clinical trials and combined with standard meta-analysis methods. An infusion with Cerebrolysin for 4 weeks (30 ml Cerebrolysin daily on five consecutive days of each week) led to a significant improvement of the clinical global impression. Compared with placebo, log(OR) was 1.1799, and 95% confident interval was 0.7463–1.6135 (P < 0.05), indicating that Cerebrolysin could significantly improve the clinical global impression in patients with mild to moderate AD. However, more convincing evidences are needed for the efficacy of Cerebrolysin on the cognitive performance and activities of daily living.

Keywords: Alzheimer’s disease, dementia, Cerebrolysin, neurotrophic therapy, clinical trials, meta-analysis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Alvarez, XA, Cacabelos, R, Laredo, M, Couceiro, V, Sampedro, C, Varela, M, Corzo, L, Fernandez-Novoa, L, Vargas, M, Aleixandre, M, Linares, C, Granizo, E, Muresanu, D, Moessler, H 2006A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer’s diseaseEur J Neurol134354PubMedCrossRefGoogle Scholar
  2. Bae, CY, Cho, CY, Cho, K, Oh, BH, Choi, KG, Lee, HS, Jung, SP 2000A double-blind, placebo-controlled, multicenter study of Cerebrolysin for Alzheimer’s diseaseJ Am Geriatr Soc4815661571PubMedGoogle Scholar
  3. Boado, RJ 2001Amplification of blood–brain barrier GLUT1 glucose transporter gene expression by brain-derived peptidesNeurosci Res40337342PubMedCrossRefGoogle Scholar
  4. Eder, P, Reinprecht, I, Schreiner, E, Skofitsch, G, Windisch, M 2001Increased density of glutamate receptor subunit 1 due to Cerebrolysin treatment: an immunohistochemical study on aged ratsHistochem J33605612PubMedCrossRefGoogle Scholar
  5. Frick, KM, Price, DL, Koliatsos, VE, Markowska, AL 1997The effects of nerve growth factor on spatial recent memory in aged rats persist after discontinuation of treatmentJ Neurosci1725432550PubMedGoogle Scholar
  6. Muresanu, DF, Rainer, M, Moessler, H 2002Improved global function and activities of daily living in patients with AD: a placebo-controlled clinical study with the neurotrophic agent CerebrolysinJ Neural Transm Suppl62277285PubMedGoogle Scholar
  7. Normand, SLT 1999Meta-analysis: formulating, evaluating, combining, and reportingStat Med18321359PubMedCrossRefGoogle Scholar
  8. Panisset, M Gauthier, S Moessler, H Windisch, M Cerebrolysin Study Group2002Cerebrolysin in Alzheimer’s disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agentJ Neural Transm10910891104PubMedCrossRefGoogle Scholar
  9. Rockenstein, E, Adame, A, Mante, M, Larrea, G, Crews, L, Windisch, M, Moessler, H, Masliah, E 2005Amelioration of the cerebrovascular amyloidosis in a transgenic model of Alzheimer’s disease with the neurotrophic compound cerebrolysinJ Neural Transm112269282PubMedCrossRefGoogle Scholar
  10. Rockenstein, E, Torrance, M, Mante, M, Adame, A, Paulino, A, Rose, JB, Crews, L, Moessler, H, Masliah, E 2006Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer’s diseaseJ Neurosci Res1512521261CrossRefGoogle Scholar
  11. Ruether, E, Rither, R, Apecechea, M, Freytag, S, Windisch, M 1994Efficacy of the peptidergic nootropic drug Cerebrolysin in patients with senile dementia of the Alzheimer type (SDAT)Pharmacopsychiatry273240CrossRefGoogle Scholar
  12. Ruether, E, Ritter, R, Apecechea, M, Freytag, S, Gmeinbauer, R, Windisch, M 2000Sustained improvements in patients with dementia of Alzheimer’s type (DAT) 6 months after termination of Cerebrolysin therapyJ Neural Transm107815829CrossRefGoogle Scholar
  13. Ruether, E, Husmann, R, Kinzler, E, Diabl, E, Klingler, D, Spatt, J, Ritter, R, Schmidt, R, Taneri, Z, Winterer, W, Koper, D, Kasper, S, Rainer, M, Moessler, H 2001A 28-week, double-blind, placebo-controlled study with Cerebrolysin in patient with mild to moderate Alzheimer’s diseaseInt Clin Psychopharmacol16253263PubMedCrossRefGoogle Scholar
  14. Ruether, E, Alvarez, XA, Rainer, M, Moessler, H 2002Sustained improvement of cognition and global function in patients with moderately severe AD: a double-blind, placebo-controlled study with the neurotrophic agent CerebrolysinJ Neural Transm Suppl62265275PubMedGoogle Scholar
  15. Seiger, A, Nordberg, A, von Holst, H, Backman, L, Ebendal, T, Alafuzoff, I, Amberla, K, Hartvig, P, Herlitz, A, Lilja, A 1993Intracranial infusion of purified nerve growth factor to an Alzheimer patient: the first attempt of a possible future treatment strategyBehav Brain Res57255261PubMedCrossRefGoogle Scholar
  16. Whitehead, A 2002Meta-analysis of controlled clinical trialJ WileyChichesterGoogle Scholar
  17. Xiao, Sf, Yan, H, Yao, P 2000Efficacy of FPF1070 (Cerebrolysin) in patients with Alzheimer’s disease: a multicenter, randomized, double-blind, placebo-controlled trialClin Drug Invest194353CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Z.-H. Wei
    • 1
  • Q.-B. He
    • 1
  • H. Wang
    • 1
  • B.-H. Su
    • 1
  • H.-Z. Chen
    • 1
  1. 1.Department of Pharmacology and Biostatistics, College of Basic Medical SciencesJiaotong UniversityShanghaiChina

Personalised recommendations